AbCellera and Incyte have for the discovery and development of therapeutic antibodies in oncology.
Incyte will gain the rights to develop and commercialise the therapeutic cancer antibodies that result from the alliance.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AbCellera will receive research payments, downstream clinical and regulatory milestone payments and royalties for net product sales from Incyte.
Incyte BioTherapeutics vice-president Patrick Mayes stated: 鈥淭his collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer.
鈥淲e are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.鈥�
AbCellera focuses on rapidly making available improved medicines by breaking barriers to the standard discovery process of antibody drugs.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIts engine merges specialist teams, technology, and the data science and automation required to expedite antibody-based therapies from target to clinic in a range of therapeutic fields.
AbCellera Partnering senior vice-president Murray McCutcheon stated: 鈥淲e are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need.
鈥淲e look forward to working as an extension of Incyte鈥檚 team to address complex antibody discovery challenges and accelerate the development of Incyte鈥檚 preclinical pipeline of oncology medicines.鈥�
In June 2023, AbCellera聽entered a research collaboration聽with Confo Therapeutics for the discovery of specific G protein-coupled receptor ligand (GPCR)-targeting antibody candidates.
